Multidimensional Accurate Diagnosis and Treatment Technology and Clinical Transformation of Type 2 Diabetes Nephropathy

NCT05888909 · tracked via the Priya Life Science China tracker

Sponsor

Chinese PLA General Hospital

Phase

Observational

Started

2022-08-01

Last updated

2023-06-05

Condition(s) studied

Diabetic Nephropathy Type 2Diabetic Kidney DiseaseType 2 Diabetes

Study summary

Diabetes nephropathy (DN) is one of the most serious microvascular complications of diabetes, and also an important cause of death and disability of diabetes patients. There is no specific clinical staging of type 2 diabetes nephropathy at home and abroad, and there is no comprehensive study to comprehensively describe the occurrence and development of type 2 diabetes nephropathy through sensitive biomarkers, microvascular disease imaging and functional detection, digital markers and other multi-dimensional diagnosis and evaluation methods. Therefore, our research aims to establish a long-term follow-up queue for the whole cycle of diabetes nephropathy, develop multi-dimensional diagnostic and progress digital markers for diabetes nephropathy, develop a multimodal non-invasive diagnostic model and a new clinical staging/typing, and create a multi-dimensional accurate diagnosis and treatment system for type 2 diabetes nephropathy combining traditional Chinese and western medicine.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: Age ≥ 18 years old, regardless of gender; Type 2 diabetes; Having a complete medical history and clinical data; If the patients with type 2 diabetes combined with CKD underwent renal biopsy, the pathological diagnosis should be clear; Patients voluntarily signs an informed consent form. Exclusion criteria: Incomplete medical history or clinical data; Patients with hereditary kidney disease; Combined urinary tract infection; Merge autoimmune system diseases; Patients with malignant tumor were expected to survive less than 6 months; Pregnancy and lactation.

Primary outcome measure(s)

change in estimated glomerular filtration rate (eGFR) from baseline — 24months
eGFR is calculated using the CKD-EPI formula, involving gender, age, and serum creatinine.

Trial sites (1)

Facility	City	Region	Status
Chinese PLA General Hospital	Beijing	China	Recruiting

More Chinese PLA General Hospital trials in China

Management of Age-Related Auditory Decline and Early Warning of Its Co-occurring Dementia Starting soon

Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant. Recruiting

Chinese, Overweight or Obesity, Real-World Registry Study Starting soon

CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas Recruiting

GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma Recruiting

Other trials for the same condition

Correlation Study Between Clinical Phenotype and Pathology of Type 2 Diabetic Nephropathy Recruiting

Henagliflozin's Impact on Prediabetes Remission Starting soon

A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes Active, not recruiting

A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes Active, not recruiting

Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Diet and Exercise Alone（UNIGUIDE-1） Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05888909 on ClinicalTrials.gov ↗ ← All trials in China